These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 26739479)

  • 21. Tolerability of the first infusion of once-yearly zoledronic acid within one to two weeks after hip fracture surgery.
    Kashii M; Kamatani T; Abe S; Yoshida A; Yamamoto K; Koizumi K; Mizuno N; Kuriyama K; Yoshikawa H
    Bone; 2022 Feb; 155():116298. PubMed ID: 34906743
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Post-surgery severe hypocalcemia in primary hyperparathyroidism preoperatively treated with zoledronic acid.
    Corsello SM; Paragliola RM; Locantore P; Ingraudo F; Ricciato MP; Rota CA; Senes P; Pontecorvi A
    Hormones (Athens); 2010; 9(4):338-42. PubMed ID: 21112866
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ectopic parathyroid hormone as a rare aetiology of hypercalcemia with rhabdomyosarcoma: a new treatment strategy with zoledronic acid and Denosumab.
    Kilci F; Demirsoy U; Jones JH; Çakır Ö; Çizmecioğlu-Jones FM
    J Pediatr Endocrinol Metab; 2022 Aug; 35(8):1107-1112. PubMed ID: 35534911
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.
    Henry DH; Costa L; Goldwasser F; Hirsh V; Hungria V; Prausova J; Scagliotti GV; Sleeboom H; Spencer A; Vadhan-Raj S; von Moos R; Willenbacher W; Woll PJ; Wang J; Jiang Q; Jun S; Dansey R; Yeh H
    J Clin Oncol; 2011 Mar; 29(9):1125-32. PubMed ID: 21343556
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Zoledronic acid for cancer therapy--induced and postmenopausal bone loss.
    Brufsky AM
    Expert Opin Pharmacother; 2008 Apr; 9(6):1013-28. PubMed ID: 18377343
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials.
    Major P; Lortholary A; Hon J; Abdi E; Mills G; Menssen HD; Yunus F; Bell R; Body J; Quebe-Fehling E; Seaman J
    J Clin Oncol; 2001 Jan; 19(2):558-67. PubMed ID: 11208851
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Zoledronic Acid-Induced Interface Dermatitis.
    Succaria F; Collier M; Mahalingam M
    Am J Dermatopathol; 2015 Dec; 37(12):933-5. PubMed ID: 26588338
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A case of acquired Fanconi syndrome induced by zoledronic acid.
    Yoshinami T; Yagi T; Sakai D; Sugimoto N; Imamura F
    Intern Med; 2011; 50(9):1075-9. PubMed ID: 21532237
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of hypercalcemia of malignancy with bisphosphonates.
    Berenson JR
    Semin Oncol; 2002 Dec; 29(6 Suppl 21):12-8. PubMed ID: 12584690
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transient disturbance in physeal morphology is associated with long-term effects of nitrogen-containing bisphosphonates in growing rabbits.
    Smith EJ; Little DG; Briody JN; McEvoy A; Smith NC; Eisman JA; Gardiner EM
    J Bone Miner Res; 2005 Oct; 20(10):1731-41. PubMed ID: 16160731
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Persistent hypocalcemia induced by zoledronic acid in a patient with androgen-independent prostate cancer and extensive bone metastases.
    Gulley JL; Wu S; Arlen PM; Dahut WL
    Clin Genitourin Cancer; 2007 Sep; 5(6):403-5. PubMed ID: 17956715
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience).
    Kraj M; Pogłód R; Maj S; Pawlikowski J; Sokołowska U; Szczepanik J
    Acta Pol Pharm; 2002; 59(6):478-82. PubMed ID: 12669777
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Feasibility and dose discovery analysis of zoledronic acid with concurrent chemotherapy in the treatment of newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group.
    Goldsby RE; Fan TM; Villaluna D; Wagner LM; Isakoff MS; Meyer J; Randall RL; Lee S; Kim G; Bernstein M; Gorlick R; Krailo M; Marina N
    Eur J Cancer; 2013 Jul; 49(10):2384-91. PubMed ID: 23664013
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ZOLEDRONIC ACID THERAPY OF PATIENTS WITH PAGET DISEASE OF BONE RESISTANT TO OR WITH UNSUSTAINED REMISSION FOLLOWING PRIOR BISPHOSPHONATE THERAPY.
    Tucci JR
    Endocr Pract; 2015 Oct; 21(10):1111-6. PubMed ID: 26151420
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hypercalcemia of malignancy remains a clinically relevant problem.
    Van Poznak C
    Cancer J; 2006; 12(1):21-3. PubMed ID: 16613658
    [No Abstract]   [Full Text] [Related]  

  • 36. Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.
    Stopeck A; Rader M; Henry D; Danese M; Halperin M; Cong Z; Qian Y; Dansey R; Chung K
    J Med Econ; 2012; 15(4):712-23. PubMed ID: 22409231
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Review of the cardiovascular safety of zoledronic acid and other bisphosphonates for the treatment of osteoporosis.
    John Camm A
    Clin Ther; 2010 Mar; 32(3):426-36. PubMed ID: 20399982
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Zoledronic Acid-Associated Fanconi Syndrome in Patients With Cancer.
    Portales-Castillo I; Mount DB; Nigwekar SU; Yu EW; Rennke HG; Gupta S
    Am J Kidney Dis; 2022 Oct; 80(4):555-559. PubMed ID: 35219759
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Denosumab for treatment of hypercalcemia of malignancy.
    Hu MI; Glezerman IG; Leboulleux S; Insogna K; Gucalp R; Misiorowski W; Yu B; Zorsky P; Tosi D; Bessudo A; Jaccard A; Tonini G; Ying W; Braun A; Jain RK
    J Clin Endocrinol Metab; 2014 Sep; 99(9):3144-52. PubMed ID: 24915117
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical significance of zoledronic acid and strontium-89 in patients with asymptomatic bone metastases from non-small-cell lung cancer.
    Wang Y; Tao H; Yu X; Wang Z; Wang M
    Clin Lung Cancer; 2013 May; 14(3):254-60. PubMed ID: 23103352
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.